Company intelligence / Profile preview

Endomedix

Montclair, New Jersey, United Statesendomedix.com ↗

Ownership: Private
Employees: ~24
Development stage: Preclinical

Overview

Endomedix has developed a patented tunable polysaccharide platform that produces new biomaterials for surgical hemostasis. Its flagship product, PlexiClot Absorbable Hemostat, is designed to rapidly control bleeding during brain and spinal surgeries. The technology forms a 3D network in situ to achieve hemostasis. There are no published pivotal or late-stage clinical results as of the latest available information.

Therapeutic areas: Neurology
Modalities: DeviceHydrogel-based drug delivery therapyBiologic (biopolymer-based)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

PlexiClot

Pre-clinical

Indications: Neurosurgical bleeding

Beyond the preview

Go deeper on Endomedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endomedix.

Explore the full profile